APPENDIX E



IOC Consensus Meeting on Sex Reassignment and Hyperandrogenism November 2015

Participants:

Prof Dr Uğur Erdener Chairman, IOC Medical & Scientific Commission

Prof Arne Ljungqvist Former Chairman, IOC Medical Commission

Dr Stéphane Bermon Monaco Institute of Sports Medicine & Surgery, IAAF Medical &

Scientific Senior Consultant

Michael Beloff, QC Barrister, Blackstone Chambers

Prof Gerard Conway Professor of Clinical Medicine, University College London

Prof Myron Genel Professor Emeritus of Pediatrics and Senior Research Scientist,

Yale Child Health Research Center Yale University School of Medicine

Ms Joanna Harper Chief Medical Physicist, Radiation Oncology, Providence

Portland Medical Center

Prof Angelica Linden

Hirschberg

Department of Woman & Child Health, Division of Obstetrics &

Gynecology, Karolinska Institutet

Prof Dr Maria Jose Martinez

Patino

Faculty of Sport Sciences, University of Vigo

Prof Martin Ritzén Professor Emeritus, Dept of Woman and Child Health

Karolinska Institutet

Dr Eric Vilain Professor of Human Genetics, Pediatrics and Urology

Director, Center for Gender-Based Biology

Chief, Medical Genetics, Department of Pediatrics

Co-director, Clinical Genomic Center David Geffen School of Medicine at UCLA

Jonathan Taylor Partner, Bird & Bird

Liz Riley Barrister, Bird & Bird

Dr Robin Mitchell Vice-Chair, IOC Medical & Scientific Commission

Dr Rania Elwani Member, IOC Medical & Scientific Commission

Dr Vidya Mohamed-Ali Member, IOC Medical & Scientific Commission

Prof Yannis Pitsiladis Member, IOC Medical & Scientific Commission

Dr Richard Budgett IOC Medical & Scientific Director

Dr Lars Engebretsen IOC Head of Scientific Activities

Christian Thill IOC Senior Legal Counsel

1) Transgender guidelines

- A. Since the 2003 Stockholm Consensus on Sex Reassignment in Sports, there has been a growing recognition of the importance of autonomy of gender identity in society, as reflected in the laws of many jurisdictions worldwide.
- B. There are also, however, jurisdictions where autonomy of gender identity is not recognised in law at all.
- C. It is necessary to ensure insofar as possible that trans athletes are not excluded from the opportunity to participate in sporting competition.
- D. The overriding sporting objective is and remains the guarantee of fair competition. Restrictions on participation are appropriate to the extent that they are necessary and proportionate to the achievement of that objective.
- E. To require surgical anatomical changes as a pre-condition to participation is not necessary to preserve fair competition and may be inconsistent with developing legislation and notions of human rights.
- F. Nothing in these guidelines is intended to undermine in any way the requirement to comply with the World Anti-Doping Code and the WADA International Standards.
- G. These guidelines are a living document and will be subject to review in light of any scientific or medical developments.

In this spirit, the IOC Consensus Meeting agreed the following guidelines to be taken into account by sports organisations when determining eligibility to compete in male and female competition:

- 1. Those who transition from female to male are eligible to compete in the male category without restriction.
- 2. Those who transition from male to female are eligible to compete in the female category under the following conditions:
 - 2.1. The athlete has declared that her gender identity is female. The declaration cannot be changed, for sporting purposes, for a minimum of four years.
 - 2.2. The athlete must demonstrate that her total testosterone level in serum has been below 10 nmol/L for at least 12 months prior to her first competition (with the requirement for any longer period to be based on a confidential case-by-case evaluation, considering whether or not 12 months is a sufficient length of time to minimize any advantage in women's competition).

- 2.3. The athlete's total testosterone level in serum must remain below 10 nmol/L throughout the period of desired eligibility to compete in the female category.
- 2.4. Compliance with these conditions may be monitored by testing. In the event of non-compliance, the athlete's eligibility for female competition will be suspended for 12 months.

2) Hyperandrogenism in female athletes

In response to the interim award dated 24 July 2015 in <u>Chand v AFI and IAAF</u> CAS 2014/A/3759, the IOC Consensus Meeting recommended:

- Rules should be in place for the protection of women in sport and the promotion of the principles of fair competition.
- The IAAF, with support from other International Federations, National Olympic Committees and other sports organisations, is encouraged to revert to CAS with arguments and evidence to support the reinstatement of its hyperandrogenism rules.
- To avoid discrimination, if not eligible for female competition the athlete should be eligible to compete in male competition.